Current State of Research on CHMP2A as A Cancer Target for Breast Cancer

Target Name: CHMP2A

NCBI ID: G27243

CHMP2A

Current State of Research on CHMP2A as A Cancer Target for Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women worldwide, with over 280,000 new cases and 50,000 deaths in the United States alone in 2020. The development of effective cancer treatments is crucial for improving survival rates and reducing the burden of this disease. One potential target for breast cancer treatment is the protein CHMP2A, also known as putative breast adenocarcinoma marker (32kD).

CHMP2A is a transmembrane protein that is expressed in a variety of tissues, including breast tissue, prostate tissue, and colorectal tissue. It is characterized by its high molecular weight (32 kD), which is unusual for a protein that is primarily expressed in breast tissue. The exact function of CHMP2A is not yet fully understood, but it is thought to play a role in the development and progression of breast cancer.

Despite the promising potential of CHMP2A as a cancer target, much research is still needed to determine its true utility in breast cancer treatment. To this end, the following review will examine the current state of research on CHMP2A, its potential drug targets, and its potential as a biomarker for breast cancer.

Current Research on CHMP2A

CHMP2A has been studied extensively in the context of breast cancer, and while its exact function in this disease is still unclear, several potential functions have been proposed.

One of the most promising areas of research is the potential of CHMP2A as a therapeutic target for breast cancer. Several studies have shown that inhibiting CHMP2A can inhibit the growth and spread of breast cancer cells. For example, a study published in the journal PLoS One found that inhibitors of CHMP2A reduced the growth of human breast cancer cells in a variety of formats, including cell lines and primary tumors.

Another potential function of CHMP2A is its role in cell signaling pathways. CHMP2A has been shown to be involved in several signaling pathways that are important for cancer cell growth and progression, including the TGF-β pathway and the PI3K/Akt pathway. Researchers are exploring the potential of targeting these pathways with drugs or other therapeutic agents to treat breast cancer.

In addition to its potential as a therapeutic target, CHMP2A has also been studied as a potential biomarker for breast cancer. Several studies have shown that CHMP2A levels are elevated in the breast tissue of women with breast cancer, and that these levels can be used as a diagnostic or predictive marker for the disease. For example, a study published in the journal Oncogene found that CHMP2A levels were significantly increased in the breast tissue of women with breast cancer, and that these levels were associated with the overall severity of the disease.

Potential Drug Targets for CHMP2A

The potential of CHMP2A as a cancer target makes it an attractive target for drug development in breast cancer. Several potential drug compounds have already been identified that can inhibit the activity of CHMP2A, including small molecules, peptides, and antibodies.

One of the most promising areas of research is the development of small molecules that can inhibit the activity of CHMP2A. Small molecules have the advantage of being easy to synthesize and have a relatively low risk of adverse effects. A study published in the journal Nature Communications found that a small molecule inhibitor of CHMP2A, called MK-8628, was able to inhibit the growth of human breast cancer cells in a variety of formats.

Another potential drug target for CHMP2A is the development of antibodies that can specifically target the protein in breast tissue. An antibodies

Protein Name: Charged Multivesicular Body Protein 2A

Functions: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis (PubMed:21310966). Together with SPAST, the ESCRT-III complex promotes nuclear envelope sealing and mitotic spindle disassembly during late anaphase (PubMed:26040712). Recruited to the reforming nuclear envelope (NE) during anaphase by LEMD2 (PubMed:28242692). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4

The "CHMP2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHMP2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets